Navigating the Crucial Clinical Trial Design Considerations for CNS Protein Degraders

Time: 9:00 am
day: Conference Day One


  • Outlining experiences of carrying out long-lasting clinical trials for neurodegenerative indications with older patient populations
  • Overcoming dosage and toxicology considerations before entering clinical trials
  • Discussing the use of biomarkers to monitor brain penetration, target engagement and degradation efficacy